How Has Abbott’s Revenue Mix Changed In The Last 5 Years?
- Nutritional and diagnostics have become an increasingly important segment for Abbott over the last five years.
- Sales from pharmaceutical products declined in 2012 due to the spin-off of Abbott’s proprietary pharmaceutical drugs business into an independent entity – AbbVie back then.
- Vascular sales have declined due to pricing pressure and high competition in the segment from rivals.
See the links below for more information and analysis about Abbott:
- What’s Abbott’s Fundamental Value Based On Expected 2016 Results?
- What is Abbott’s Revenue And Gross Profit Breakdown?
- By What Percentage Did Abbott’s Revenue & Gross Profits Grow In The Last 5 Years?
Relevant Articles
- Should You Pick Abbott Stock At $105 After An Upbeat Q1?
- After Nearly A 20% Rise In Six Months Will Abbott Stock See Higher Levels Post Q1?
- What’s Next For Abbott Stock After A 6% Rise This Year?
- Is Abbott Stock Undervalued At $95?
- Which Is A Better Pick – Abbott Stock Or Amgen?
- Is Abbott Stock A Better Healthcare Pick Over Thermo Fisher Scientific?
Notes:
1) The purpose of these analyses is to help readers focus on a few important things. We hope such lean communication sparks thinking, and encourages readers to comment and ask questions on the comment section, or email content@trefis.com
2) Figures mentioned are approximate values to help our readers remember the key concepts more intuitively. For precise figures, please refer to our complete analysis for Abbott